The last few years have seen an increasing number of cell and gene therapies approved. By their nature, they are exceptionally expensive. And while they offer tremendous life saving potential, healthcare systems are going to have to figure out how to pay for them. Conveniently timed, with the news of Kymriah being made available to qualifying patients through the NHS – STAT news have put together a great article assessing the need for health care systems to get on top of the payment issue quickly. Give it a read!